Admedes Schuessler GmbH, Germany, has strategically invested $80 million in its operations in Pforzheim, Germany, to expand Nitinol manufacturing and to develop new technologies to support the medical device industry’s rapid pace of innovation. Admedes is focusing on increasing the level of automation in serial production lines and expanding lean manufacturing methods. The investments will effectively double the production area and improve efficiencies.
The expansion includes a new building that adds 195,000 ft2 for production, labs, offices, and space for the new Admedes Innovation Center. This brings together Admedes expert engineering and scientific teams for the development of new technologies that will enable new applications, materials, and design options for medical device companies.
“The investment will secure our position as the leading manufacturer of Nitinol implants. Combined with continued innovation in Admedes’ offerings, we will solidify our competitiveness and attractiveness to our customers,” stated Dr. Andreas Schuessler, founder and CEO. “With the extraordinary quality we deliver, the high flexibility, efficiencies, and economies of scale, we can continue to attract customers who do their Nitinol production in-house. Outsourcing will be made very attractive for them.”
The ground-breaking ceremony was held in September 2012 and the new building has been occupied since early this year.
